Your browser doesn't support javascript.
loading
Cardiovascular Risk in Patients with Hematological Malignancies: A Systematic Review and Meta-Analysis.
Yong, Jung Hahn; Mai, Aaron Shengting; Matetic, Andrija; Elbadawi, Ayman; Elgendy, Islam Y; Lopez-Fernandez, Teresa; Mamas, Mamas A.
Afiliación
  • Yong JH; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Mai AS; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
  • Matetic A; Department of Cardiology, University Hospital of Split, Split, Croatia; Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, United Kingdom.
  • Elbadawi A; Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Elgendy IY; Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, Kentucky.
  • Lopez-Fernandez T; Cardiology Department, La Paz University Hospital, IdiPAZ Research Institute, Madrid, Spain.
  • Mamas MA; Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, United Kingdom. Electronic address: mamasmamas1@yahoo.co.uk.
Am J Cardiol ; 212: 80-102, 2024 Feb 01.
Article en En | MEDLINE | ID: mdl-38042266
Patients with hematologic malignancies (HMs) are at risk of future cardiovascular (CV) events. We therefore conducted a systematic review and meta-analysis to quantify their risk of future CV events. We searched Medline and EMBASE databases from inception until January 31, 2023 for relevant articles using a combination of keywords and medical subject headings. Studies examining CV outcomes in patients with HM versus controls without HM were included. The outcomes of interest included acute myocardial infarction (AMI), heart failure (HF), and stroke. The outcomes were expressed as hazard ratios (HRs) and their 95% confidence intervals (CIs). This study is registered with PROSPERO at CRD42022307814. A total of 15 studies involving 1,960,144 cases (178,602 patients with HM and 1,781,212 controls) were included in the quantitative analysis. A total of 10 studies examined the risk of AMI, 5 examined HF, and 11 examined stroke. Compared with the control group, the HRs for HM for AMI, HF, and stroke were 1.65 (95% CI 1.29 to 2.09, p <0.001), 4.82 (95% CI 3.72 to 6.25, p <0.001), and 1.60 (95% CI 1.30 to 1.97, p <0.001), respectively. The sensitivity analysis of stroke risk based on lymphoma type showed an increased risk of stroke in patients with non-Hodgkin lymphoma compared with controls (HR 1.31, 95% CI 1.04 to 1.64, p = 0.03) but no significant difference for Hodgkin lymphoma (HR 1.67, 95% CI 0.86 to 3.23, p = 0.08). Patients with HM are at increased risk of future AMI, HF, and stroke, and these findings suggest that CV care of patients with HM should be considered as a growing priority.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Neoplasias Hematológicas / Factores de Riesgo de Enfermedad Cardiaca Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Am J Cardiol Año: 2024 Tipo del documento: Article País de afiliación: Singapur Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Neoplasias Hematológicas / Factores de Riesgo de Enfermedad Cardiaca Tipo de estudio: Systematic_reviews Límite: Humans Idioma: En Revista: Am J Cardiol Año: 2024 Tipo del documento: Article País de afiliación: Singapur Pais de publicación: Estados Unidos